Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ricin Toxin A Conjugated Monoclonal Antibodies
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Veloxis Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : T-Guard (ricin toxin A conjugated mAB) is designed to reset the body's immune system in life-threatening T cell‒mediated conditions, potentially including prevention of transplant-related rejection, treatment of acute solid-organ rejection, and severe ...
Brand Name : T-Guard
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2022
Lead Product(s) : Ricin Toxin A Conjugated Monoclonal Antibodies
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Veloxis Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ricin Toxin A Conjugated Monoclonal Antibodies
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : T-Guard (ricin toxin A conjugated mAB) is designed to safely and swiftly reset the body’s immune system in life-threatening T cell‒mediated conditions, including transplant-related rejection, acute solid-organ rejection, and severe autoimmune disease...
Brand Name : T-Guard
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 27, 2022
Lead Product(s) : Ricin Toxin A Conjugated Monoclonal Antibodies
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?